ATE546157T1 - Anti-pecam-therapie zur unterdrückung von metastasen - Google Patents

Anti-pecam-therapie zur unterdrückung von metastasen

Info

Publication number
ATE546157T1
ATE546157T1 AT04810905T AT04810905T ATE546157T1 AT E546157 T1 ATE546157 T1 AT E546157T1 AT 04810905 T AT04810905 T AT 04810905T AT 04810905 T AT04810905 T AT 04810905T AT E546157 T1 ATE546157 T1 AT E546157T1
Authority
AT
Austria
Prior art keywords
suppressing metastasis
pecam
therapy
pecam therapy
metastasis
Prior art date
Application number
AT04810905T
Other languages
English (en)
Inventor
Robert Debs
Original Assignee
Sutter West Bay Hospitals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutter West Bay Hospitals filed Critical Sutter West Bay Hospitals
Application granted granted Critical
Publication of ATE546157T1 publication Critical patent/ATE546157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT04810905T 2003-11-13 2004-11-12 Anti-pecam-therapie zur unterdrückung von metastasen ATE546157T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51998603P 2003-11-13 2003-11-13
PCT/US2004/037924 WO2005048938A2 (en) 2003-11-13 2004-11-12 Anti-pecam therapy for metastasis suppression

Publications (1)

Publication Number Publication Date
ATE546157T1 true ATE546157T1 (de) 2012-03-15

Family

ID=34619413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04810905T ATE546157T1 (de) 2003-11-13 2004-11-12 Anti-pecam-therapie zur unterdrückung von metastasen

Country Status (7)

Country Link
US (2) US7572443B2 (de)
EP (1) EP1691836B1 (de)
JP (1) JP4897490B2 (de)
AT (1) ATE546157T1 (de)
CA (1) CA2541709C (de)
ES (1) ES2382942T3 (de)
WO (1) WO2005048938A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076795A1 (en) * 2010-09-27 2012-03-29 Sutter West Bay Hospitals D/B/A California Pacific Medical Center Anti-PECAM Therapy, Compositions, Methods, and Uses
WO2020040523A1 (ko) * 2018-08-20 2020-02-27 연세대학교 산학협력단 혈관 내피세포 순수 분리를 위한 항체 및 이의 제조 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2108048T3 (es) * 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0940468A1 (de) * 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US5912160A (en) 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
JP4018854B2 (ja) * 1999-10-28 2007-12-05 第一三共株式会社 抗悪性腫瘍薬
US7285382B2 (en) 2000-01-25 2007-10-23 Genentech, Inc. Compositions and methods for treatment of cancer
US7776612B2 (en) * 2001-04-13 2010-08-17 Chugai Seiyaku Kabushiki Kaisha Method of quantifying antigen expression
EP1381384B1 (de) 2001-04-24 2011-05-25 Merck Patent GmbH KOMBINATIONSTHERAPIE MIT ANTIANGIOGENEN MITTELN UND TNFalpha
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)

Also Published As

Publication number Publication date
WO2005048938A2 (en) 2005-06-02
CA2541709A1 (en) 2005-06-02
EP1691836A4 (de) 2008-02-13
ES2382942T3 (es) 2012-06-14
US20090285828A1 (en) 2009-11-19
US7572443B2 (en) 2009-08-11
JP2007511531A (ja) 2007-05-10
JP4897490B2 (ja) 2012-03-14
WO2005048938A3 (en) 2005-10-06
US20050186213A1 (en) 2005-08-25
EP1691836A2 (de) 2006-08-23
EP1691836B1 (de) 2012-02-22
CA2541709C (en) 2013-06-04

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
MY142988A (en) Novel aminobenzophenone compounds
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
IL244803A0 (en) Human anti-beta7 antibodies and their use
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
ATE461217T1 (de) Glp-1-verbindungen
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
SE0301653D0 (sv) Novel compounds
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
DK1895017T3 (da) Anvendelse af A33-antigener og JAM-IT
NO20055741D0 (no) Nye kjemiske forbindelser
SE0301650D0 (sv) Novel compounds
DE60329326D1 (de) Tace inhibitoren
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
TW200716132A (en) Novel chemical compounds
ATE546157T1 (de) Anti-pecam-therapie zur unterdrückung von metastasen